Archives of Medical Research
Volume 41, Issue 4 , Pages 297-301 , May 2010

Is Dysfunction of Caveolin-1 a Link Between Systemic Sclerosis and Breast Cancer, Opening a Window on Both Etiologies?

  • Niansong Qian

      Affiliations

    • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • Department of Hepatobiliary Surgery, Chinese People's Liberation Army General Hospital, Beijing, China
    • Department of Hepatobiliary surgery, Chinese People's Liberation Army 302 Hospital, Beijing, China
    • ,
  • Takayuki Ueno

      Affiliations

    • Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • Corresponding Author InformationAddress reprint requests to: Takayuki Ueno, Kyoto University, 54 shogoin-Kawahara Cho, Sakyo-Ku, Kyoto, Japan; Phone: +81-75-751-3660; FAX: +81-75-751-3616

Received 21 February 2010 ,Accepted 25 May 2010.

References 

  1. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223–235
  2. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis. 2007;66:551–553
  3. Derk CT, Rasheed M, Artlett CM, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33:1113–1116
  4. Derk CT. Associations of breast cancer development in patients with systemic sclerosis: an exploratory study. Clin Rheumatol. 2007;26:1615–1619
  5. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res. 2008;10:201
  6. Oliver JE, Silman AJ. Why are women predisposed to autoimmune rheumatic diseases?. Arthritis Res Ther. 2009;11:252
  7. Oliver JE, Silman AJ. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther. 2009;11:223
  8. Lambe M, Björnådal L, Neregård P, et al. Childbearing and the risk of scleroderma: a population-based study in Sweden. Am J Epideimol. 2004;15(159):162–166
  9. Artlett CM, Rasheed M, Russo-Stieglitz KE, et al. Influence of prior pregnancies on disease course and cause of death in systemic sclerosis. Ann Rheum Dis. 2002;61:346–350
  10. Tuma R. Mimicking pregnancy to reduce breast cancer risk. J Natl Cancer Inst. 2010;21:517–518
  11. Tan FK, Arnett FC. Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol. 2000;12:511–519
  12. Tan FK, Wang N, Kuwana M, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum. 2001;44:893–901
  13. Hoshi M, Yasuoka H, Kuwana M. Estrogen receptor gene polymorphisms in Japanese patients with systemic sclerosis. Clin Exp Rheumatol. 2008;26:914–917
  14. Tourkina E, Gooz P, Pannu J, et al. Opposing effects of protein kinase C alpha and protein kinase C epsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem. 2005;280:13879–13887
  15. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;28(293):2449–2452
  16. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;12:38121–38138
  17. Odajima N, Betsuyaku T, Nasuhara Y, et al. Loss of caveolin-1 in bronchiolization in lung fibrosis. J Histochem Cytochem. 2007;55:899–909
  18. Galdo FD, Sotgia F, de Almeida CJ, et al. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008;58:2854–2865
  19. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;25(3729):1502–1517
  20. Achiron A, Barak Y, Gail M, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat. 2005;89:265–270
  21. Shin T, Kim H, Jin JK, et al. Expression of caveolin-1, -2, and -3 in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005;165:11–20
  22. Heshmati Y, Mirabzadeh A, Feizzade G, et al. A novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer's disease; extra-short alleles and accumulated allele homozygosity. Am J Med Genet B Neuropsychiatr Genet. 2009;5(150B):248–253
  23. Zarif Yeganeh M, Mirabzadeh A, Khorram Khorshid HR, et al. Novel extreme homozygote haplotypes at the human caveolin 1 gene upstream purine complex in sporadic Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2010;5(153B):347–349
  24. Zarif Yeganeh M, Ghaffarpour M, Farhud DD, et al. Skew in the human caveolin 1 gene upstream purine complex homozygote haplotype compartment in multiple sclerosis. J Neuroimmunol. 2009;30(216):103–107
  25. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. 2003;48:1964–1978
  26. Sotgia F, Rui H, Bonuccelli G, et al. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 2006;15(66):10647–10651
  27. Fu M, Wang C, Li Z, et al. Cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439–5447
  28. Zhang W, Razani B, Altschuler Y, et al. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J Biol Chem. 2000;275:20717–20725
  29. Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279:51630–51646
  30. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009;174:2023–2034
  31. Witkiewicz AK, Dasgupta A, Nguyen KH, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther. 2009;8:1071–1079
  32. Williams TM, Sotgia F, Lee H, et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol. 2006;169:1784–1801
  33. Sotgia F, Schubert W, Pestell RG, et al. Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling. Cancer Biol Ther. 2006;5:292–297
  34. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142
  35. Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 2008;25:657–663
  36. Yamauchi Y, Kohyama T, Takizawa H, et al. Tumor necrosis factor-alpha enhances both epithelial-mesenchymal transition and cell contraction induced in A549 human alveolar epithelial cells by transforming growth factor-beta1. Exp Lung Res. 2010;36:12–24
  37. Sotgia F, Williams TM, Schubert W, et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol. 2006;168:292–309
  38. Chambaz EM, Souchelnitskiy S, Pellerin S, et al. Transforming growth factors-beta s: a multifunctional cytokine family. Implication in the regulation of adrenocortical cell endocrine functions. Horm Res. 1996;45:222–226
  39. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1:169–178
  40. Hoodless PA, Wrana JL. Mechanism and function of signaling by the TGF beta superfamily. Curr Top Microbiol Immunol. 1998;228:235–272
  41. Macías-Silva M, Abdollah S, Hoodless PA, et al. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 1996;27(87):1215–1224
  42. Razani B, Zhang XL, Bitzer M, et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem. 2001;276:6727–6738
  43. Jasmin JF, Mercier I, Dupuis J, et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation. 2006;114:912–920

PII: S0188-4409(10)00135-9

doi: 10.1016/j.arcmed.2010.05.009

Archives of Medical Research
Volume 41, Issue 4 , Pages 297-301 , May 2010

Article Tools